Opus Genetics IRD Proceeds from issuance of warrants in connection with the March 2025 offering and March 2025 private placement
Proceeds from issuance of warrants in connection with the March 2025 offering and March 2025 private placement at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept ird:ProceedsFromIssuanceOfWarrantsInConnectionWithPrivateOfferingAndPrivatePlacement.
The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opus Genetics's proceeds from issuance of warrants in connection with the march 2025 offering and march 2025 private placement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opus Genetics's proceeds from issuance of warrants in connection with the march 2025 offering and march 2025 private placement?
- Opus Genetics (IRD) reported proceeds from issuance of warrants in connection with the march 2025 offering and march 2025 private placement of $0 in Q1 2026.
- How has Opus Genetics's proceeds from issuance of warrants in connection with the march 2025 offering and march 2025 private placement changed year-over-year?
- Opus Genetics's proceeds from issuance of warrants in connection with the march 2025 offering and march 2025 private placement decreased by 100.0% year-over-year, from $15.52M to $0.
- What does proceeds from issuance of warrants in connection with the march 2025 offering and march 2025 private placement mean?
- Represents the cash proceeds received specifically from the issuance of warrants as part of a broader financing package. Warrants are often used as a sweetener to attract investors, and this metric quantifies the immediate cash benefit of these instruments. It is important for understanding the potential future dilution and the current cash position.